Fairvalue-Calculator Fairvalue-Calculator
EN DE

Pharmala Biotech Holdings (MDXXF) Fair Value & Analysis

Healthcare · US · Market cap $11.6M

Price$0.1000
Fair Value$0.0100
Upside-90.0%
Quality95/100
Evidence: Low Range $0.0100 – $0.0100

Fair value as of: Jun 26, 2026

Analysis

Pharmala Biotech Holdings (MDXXF) currently trades at $0.1000, while our model-based Fair Value estimate is $0.0100 — implying the stock looks roughly 90.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Pharmala Biotech Holdings (MDXXF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0100 versus a price of $0.1000 — about −90% (overvalued). Model-based estimate, not financial advice.
What is the fair value of MDXXF?
Our 21-model fair value for Pharmala Biotech Holdings is $0.0100 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.1000.
What is the quality score of MDXXF?
Pharmala Biotech Holdings has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.